Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Cardiac Biomarker Indicates Fluid Overload in Dialysis Patients

By HospiMedica International staff writers
Posted on 07 Jun 2010
A new study has found that N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP), a cardiac biomarker in dialysis patients, can also serve as a fluid overload biomarker for the management of patients with kidney disease.

Researchers at University College London (UCL; United Kingdom) determined the pre- and post-dialysis body volume status in 72 stable hemodialysis outpatients by multifrequency bioimpedance, and then established the determined value relationship measured to NTproBNP values. More...
The patients also underwent tests of heart function.

The researchers found that the mean values of NTproBNP were 931.9 pmol/L (predialysis), compared to 242 pmol/L (postdialysis); on a simple correlation, the NTproBNP values were found to be associated with markers of volume overload and cardiac dysfunction. However, on logistical regression analysis, the strongest association was with the predialysis ratio of extracellular water to total body water, followed by postdialysis mean arterial blood pressure, dialysate calcium concentration, and change in extracellular fluid volume with dialysis. The researchers therefore concluded that NT-proBNP levels were most associated with indicators of fluid overload. The results of the study contrast with previous studies that suggest NT-proBNP might be a useful biomarker to predict increased risk of cardiovascular events and death in patients with kidney disease. The study was published ahead of print on May 27, 2010, in the Clinical Journal of the American Society of Nephrology (CJASN).

"Though this ‘cardiac biomarker' now appears to be more closely related to fluid status than to heart function, an association with heart dysfunction was found in those who had a history of hypertension and were taking beta blockers,” said lead author Andrew Davenport, M.D., and colleagues of the center of nephrology at UCL medical school. "However, because bioimpedance results can also be affected by malnutrition with loss of cell mass, NTproBNP may be elevated not only in patients with volume overload, but also those with malnutrition.”

NT-proBNP is a 76 amino acid N-terminal fragment of brain natriuretic peptide produced by overworked or damaged heart ventricles, accompanied by the loss of sodium through urine. Both BNP and NT-proBNP levels in the blood are used for screening and diagnosis of acute congestive heart failure (CHF) and may be useful in establishing prognosis as well, as both markers are typically higher in patients with worse outcome. The plasma concentrations of both BNP and NT-proBNP are also typically increased in patients with left ventricular dysfunction.

Related Links:
University College London




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.